行情

GLMD

GLMD

Galmed制药
NASDAQ

实时行情|Nasdaq Last Sale

1.538
-0.072
-4.45%
盘后: 1.530 -0.009 -0.55% 16:24 01/21 EST
开盘
1.600
昨收
1.610
最高
1.641
最低
1.500
成交量
7.76万
成交额
--
52周最高
6.25
52周最低
1.500
市值
3,858.91万
市盈率(TTM)
-1.0255
分时
5日
1月
3月
1年
5年
Galmed gains 5% after securing three new U.S. patents for Aramchol and meglumine salt
Galmed Pharmaceuticals (NASDAQ:GLMD) perks up 5% premarket after announcing that the USPTO has granted new patents related to the use of Aramchol for the treatment of fibrosis and for modulating gut microbiota.
Seekingalpha · 01/11 13:31
BRIEF-Galmed Continues To Drive Innovation With Three New US Patents Granted For Aramchol And Its Meglumine Salt
reuters.com · 01/11 12:51
Galmed 宣布 Aramchol 及其葡甲胺盐的新专利
TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and
Benzinga · 01/11 12:31
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed n...
PR Newswire · 01/11 12:30
Galmed 潜在的溃疡性结肠炎候选药物在早期研究中表现出令人鼓舞的行动
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) 
Benzinga · 01/10 14:14
Galmed Announces Results Of Phase 1 Study Of Amilo-5MER Demonstrating Safety And Tolerability
 Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a
Benzinga · 01/10 12:46
BRIEF-Galmed Announces Positive Results Of Phase 1 Study Of AMILO-5MER
reuters.com · 01/10 12:36
Galmed announces positive results of Phase 1 study of Amilo-5MER
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results of a Phase 1 clinical trial of Amilo-5MER in healthy volunteers that d...
PR Newswire · 01/10 12:30
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解GLMD最新的财务预测,通过GLMD每股收益,每股净资产,每股现金流等数据分析Galmed制药近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

20.00%强力推荐
80.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测GLMD价格均价为17.60,最高价位25.00,最低价为6.00。
最高25.00
均价17.60
最低6.00
现价1.538
EPS
实际EPS
预期EPS
-0.38-0.29-0.19-0.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 41
机构持股: 539.09万
持股比例: 21.49%
总股本: 2,508.39万
类型机构数股数
增持
6
5.51万
建仓
4
3.89万
减持
5
63.57万
平仓
3
4.22万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-1.82%
制药与医学研究
-1.11%
高管信息
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Yohai Stenzler
Chief Operating Officer
Guy Nehemya
Chief Scientific Officer
Liat Hayardeny
Lead Director/Independent Director
David Sidransky
Director
Marshall Heinberg
Independent Director
Carol Brosgart
Independent Director
Shmuel Nir
Independent Director
Amir Poshinski
暂无数据
GLMD 简况
Galmed Pharmaceuticals是一家以色列的临床阶段生物制药公司。该公司的业务重点是开发治疗肝脏疾病的疗法。该公司的主要产品是Arachmol,这是一种肝脏靶向硬脂酰辅酶A去饱和酶1,用于口服治疗NASH(非酒精性脂肪性肝炎)。

微牛提供Galmed Pharmaceuticals Ltd(NASDAQ-GLMD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的GLMD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易GLMD股票基本功能。